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Abstract: Advances in chemotherapy and surgery allows the majority of patients to survive 
cancer diseases. Yet, the price may be a proportion of patients dying of complications due to 
treatment-induced infectious complications, such as neutropenia. With the aim of decreasing 
morbidity and mortality related to infectious complications, recombinant human granulocyte 
colony-stimulating factor (G-CSF), filgrastim, and pegylated filgrastim have been used to reduce 
time and degree of neutropenia. A biosimilar is a copy of an approved original biologic medicine 
whose data protection has expired. The patent for filgrastim expired in Europe in 2006 and in 
the US in 2013. This review analyses the available evidence to be considered in order to design 
a strategy of use of G-CSF and its biosimilars. The clinical and safety outcomes of biosimilars 
are well within the range of historically reported data for originator filgrastim. This underscores 
the clinical effectiveness and safety of biosimilar filgrastim in daily clinical practice. Biosimilars 
can play an important role by offering the opportunity to reduce costs, thus contributing to the 
financial sustainability of treatment programs.
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Introduction
Recent advances in chemotherapy and surgery allows the majority of patients to sur-
vive cancer diseases. Yet, the price of intensified chemotherapy may be a proportion of 
patients dying of complications of major morbidities due to treatment-induced infec-
tious complications. Indeed, cure may require neutropenia, which, although transient 
and reversible, may sometimes be as profound and prolonged as to cause episodes of 
persistent fever requiring hospitalization.1,2
Neutropenia may not only be more severe in patients undergoing induction therapy 
for acute leukemia, or in the preengraftment phase of hematopoietic stem cell trans-
plantation, particularly allogeneic, but also in some patients receiving standard-dose 
chemotherapy for other neoplasms. With the aim of decreasing morbidity and mortality 
related to infectious complications, recombinant human granulocyte colony-stimulating 
factor (G-CSF), filgrastim, and pegylated filgrastim have been used to reduce time 
and degree of neutropenia.
Definitions
Neutropenia
The risk of infection rises as the neutrophil count falls below 500 µL−1 and is most 
related to the number of circulating neutrophils. Although various definitions have 
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been reported, the most common is the presence of absolute 
neutrophil count of less than 500 µL−1, or expected to decrease 
to ,500 µL−1 within the next 48 hours.3 Profound neutropenia 
is defined as an absolute neutrophil count ,100 µL−1.
Fever
In a neutropenic patient fever is a single episode of tempe-
rature .38.3°C (101.3°F) or a temperature .38°C (100.4°F) 
sustained for more than 1 hour.3 However, infection in neu-
tropenic and immunocompromised patients may develop in 
the absence of fever, particularly in elderly or patients treated 
with corticosteroids.
Granulocyte colony stimulating factors
They are biological growth factors that promote the prolifera-
tion, differentiation, and activation of neutrophils in the bone 
marrow. GCSF works by reducing the transition time from 
stem cell to mature neutrophil, resulting in a larger number 
of functional and mature circulating neutrophils.4
The most commonly used type of recombinant G-CSF 
is filgrastim.
Strategy of use of G-CSF
The risk of developing fever in patients treated with che-
motherapy is the most important factor to determine the 
indication for prophylactic G-CSF. The risk is related to the 
intensity of chemotherapy, the presence and degree of injury 
to the gastrointestinal mucosa, the presence of underlying 
damage to the patient’s hematopoietic stem cells, the con-
current use of radiation, and the overall clinical status of the 
patient (ie, age and comorbid conditions).4
The use of G-CSF after the administration of chemo-
therapy may be different:
•	 “Primary prophylaxis,” when neutropenia is expected to 
occur following a course of chemotherapy, but the patient 
has never experienced it.
•	 “Secondary prophylaxis,” when the patient had a neutro-
penic fever in a previous course of similar chemotherapy 
and is thus expected to do so again.
•	 “Supportive” in the attempt to shorten the duration of 
severe chemotherapy-induced neutropenia in patients 
without fever (“afebrile neutropenia”).
Administration of G-CSF is generally not recommended 
for routine treatment in patients with established fever and 
neutropenia.3
Primary prophylaxis
May be used to decrease neutropenic fever and days of hos-
pitalization, but also to maintain dose-intense chemotherapy, 
if survival benefits may be achieved. The use of CSFs was 
suggested previously in those cases in which the incidence 
of the neutropenic fever after a given regimen was 40%.5 
Recent guidelines3,6–9 suggest extending this use, inasmuch, 
they recommend primary prophylaxis when the anticipated 
incidence of neutropenic fever is in the range of 20% or 
higher with a given regimen, and no other equally safe and 
effective regimen not requiring CSF is available. This was 
based on randomized trials showing that primary prophylaxis 
was cost-effective when the risk of neutropenic fever with a 
specific regimen exceeded 20%.8,9
Evidence from multiple randomized trials and meta-
analyses supports the benefit of primary prophylaxis in reduc-
ing the frequency of hospitalization for antibiotic therapy, 
documented infection, and the rates of neutropenic fever in 
adults.10–12 The impact on survival (both short-term and long-
term), and the effect in children, are less clear.13–17
The continued use of primary G-CSF prophylaxis during 
all chemotherapy cycles is supported by a randomized trial in 
women receiving chemotherapy for breast cancer. The trial 
was closed prematurely after an interim analysis disclosing 
a higher rate of febrile neutropenia in the group receiving 
G-CSF during the first two cycles only (36% vs 10%).18
American Society of Clinical Oncology guidelines 2015 
recommend primary prophylaxis with CSFs for selected 
situations, such as patients aged 65 and older with diffuse 
aggressive lymphoma treated with curative chemotherapy, 
especially in the presence of comorbidities, or patients receiv-
ing dose-dense chemotherapy regimens that are supported 
by convincing efficacy data. Yet, the secondary – rather than 
primary – prophylaxis is preferred in all other conditions.7 
Concerns are reported about the possible increase of pul-
monary toxicity induced by the association of G-CSFs in 
patients with Hodgkin lymphoma receiving bleomycin. Yet, 
specific data are not available; toxicity is not reported with 
the same association in other types of cancer.19 Some clinical 
conditions may enhance the risk of adverse outcome, thus 
alleviating the choice to associate G-CSF (Table 1).
Table 1 Risk factors for poor clinical outcomes of febrile neutro­
penia or infection
•  Age more than 65 years
•  Absolute neutrophil count ,0.1/109/L
•  Neutropenia expected to last more than 10 days
•  invasive fungal infection
•  All clinically documented infections (fungal infection, pneumonia, 
sepsis syndrome)
•  Hospitalization at the time of fever
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Secondary prophylaxis
Secondary prophylaxis is the administration of a G-CSF 
after a cycle complicated by a neutropenic fever episode. 
A prior episode of fever during neutropenia is a risk factor 
for developing fever during neutropenia in later cycles, 
with recurrences in 50%–60% of patients.20 This practice 
reduces the risk of a neutropenic fever by approximately 
one-half.21 The target is to maintain chemotherapy dose-
intensity avoiding dose reduction; but a dose reduction may 
be the first therapeutic choice if the chemotherapy is not 
curative.5 No published regimen has ever shown improved 
disease-free or overall survival when secondary prophylaxis 
was instituted and the dose of chemotherapy maintained in 
any setting.
Treatment of patients with neutropenia
No role is established for G-CSFs in afebrile patients who 
developed severe neutropenia after chemotherapy. There 
is recommendation against their use, and also not to use 
G-CSFs routinely as an adjunct to antibiotics, except for 
patients who remain neutropenic and febrile after the initia-
tion of antibiotics.7
Side effects
Local reactions have included bruising and erythema at the 
injection site.
The use of growth factors is associated with a risk of general 
side effects, among which are fatigue (11%), generalized weak-
ness (4%), and unspecified pain (2%).22 A common side effect 
is musculoskeletal and bone pain in ∼22% of patients; transient 
hypotension has been reported, primarily associated with fil-
grastim intravenous administration. Chest pain was reported by 
5% of patients receiving filgrastim following myelosuppressive 
chemotherapy. Transient increase in alkaline phosphatase and 
lactate dehydrogenase was reported in 28%–57% of patients. 
Acute respiratory distress syndrome, glomerulonephritis, 
alveolar hemorrhage and hemoptysis, capillary leak syndrome, 
leukocytosis cutaneous vasculitis, Sweet’s syndrome (acute 
febrile neutrophilic dermatosis), and reactivation of pseudo-
gout have been reported.23
Hematologic complications include acute arterial throm-
bosis, thought to be due to filgrastim-induced platelet aggre-
gation; occasionally petechiae, thrombocytopenia, anemia, 
myelodysplasia and myeloid leukemia, and sickle cell crisis, 
splenic rupture and splenomegaly.
Dermatologic reactions associated with filgrastim are alo-
pecia (18%), generalized maculopapular rash (6%), revers-
ible exacerbations of acne, and Sweet’s syndrome (acute 
febrile neutrophilic dermatosis). Filgrastim administration 
has also been associated with rare exacerbations of psoriasis 
and vasculitis.
Gastrointestinal involvement is quite frequent: diarrhea 
(14%), mucositis (12%), anorexia (9%), constipation (5%), 
stomatitis (5%), and sore throat (4%) have been reported. 
Respiratory symptoms include dyspnea (9%), cough (6%), 
and alveolar hemorrhage and hemoptysis.
Hypersensitivity-type reactions have been primarily 
associated with intravenous administration, with dermato-
logic (rash, urticaria, facial edema), respiratory (wheezing, 
dyspnea), or cardiovascular (hypotension, bradycardia) 
alterations. Anaphylaxis following a first dose of filgrastim 
has also been reported.
Rarely, renal and endocrine (such as reversible clinical 
hypothyroidism) adverse effects have occurred.
Metabolic changes have included reversible increases in 
uric acid concentrations in 28%–57% of patients. G-CSF-
induced decreased bone mineral density was reported in a 
Washington University School of Medicine study in mice,24 as 
well as in children with severe chronic neutropenia receiving 
chronic treatment with filgrastim.23
Since several hematopoietic and nonhematopoietic 
cell types express myeloid growth factor receptors, 
there has been a concern that certain malignant cell 
lineages might respond to therapy with a granulocyte 
CSF, potentially worsening the underlying condition, 
or by triggering the development of malignancy in a 
susceptible individual. Because of this issue, the use of 
G-CSFs has been limited in patients undergoing induc-
tion therapy for acute myeloid leukemia. In a systematic 
review of 25 randomized trials of chemotherapy with or 
without G-CSF for a variety of neoplasms,25 although 
Acute myeloid leukemia/myelodysplastic syndrome 
was reported in significantly more patients treated with 
G-CSF, all-cause mortality was significantly lower in 
patients receiving chemotherapy with G-CSF, and greater 
reductions in mortality were observed in patients who 
received greater chemotherapy dose intensity. Thus, 
while the use of myeloid growth factors during chemo-
therapy might someway increase the risk of a therapy-
related myeloid neoplasm, the absolute magnitude of the 
risk is small, and the risk is probably outweighed by the 
benefits of using CSFs in this setting.
A special mention should be made about patients with 
severe congenital neutropenia who benefit from long-lasting 
replacement therapy with G-CSF. In these subjects, a special 
propensity to develop acute myeloid leukemia/ myelodysplastic 
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syndrome was reported, thus suggesting adapting the G-CSF 
schedule especially on long-lasting therapies.26,27
Biosimilars in the treatment  
of neutropenia
A biosimilar is a copy of an approved original biologic 
medicine whose data protection has expired.28 The patent 
for filgrastim expired in Europe in 2006 and in the US in 
2013.
Since the manufacturing processes remain proprietary, 
biosimilars are manufactured using independently devel-
oped proprietary process. Thus, the new biosimilar drug 
is a complex molecule of biological origin, produced with 
different methods, not chemically identical to the origina-
tor. It must be assessed more rigorously than generics, 
and thus not surprisingly the regulatory requirements of 
the European Medicines Agency (EMA) for the approval 
of biosimilars are more demanding.29 Biosimilars have 
to prove efficacy and safety comparable to the original 
product.30
On the other hand, biosimilars can play an important 
role by offering the opportunity to reduce costs, thus 
contributing to the financial sustainability of treatment 
programs.30 Concerns were raised among hematologists 
on the use of biosimilar G-CSF in stem cell transplant 
until sufficient efficacy and safety data have been col-
lected.31 In response, several centers have initiated stud-
ies in neutropenic patients, in autologous and allogeneic 
transplantation. The results have shown the benefit of 
biosimilars for this indication, supporting the extrapola-
tion by EMA.32
Available evidence for equivalence between biosimilar 
G-CSF and the originator products comprises identical or very 
similar amino-acid sequence and production in Escherichia 
coli,32 results of trials in patients and volunteers,33 in neutro-
penic patients,34,35 during autologous36,37 as well as allogeneic 
stem cell mobilization in adults and children.38,39
EMA has approved several biosimilar versions, three of 
which are commercially available (Table 2).31 In March 2015 
came the first approval for a biosimilar in the US – Zarxio, 
Novartis’ copy of Amgen’s white blood cell-boosting product 
Neupogen (filgrastim). The drug is used to reduce the risk of 
infection during chemotherapy.40
Prophylaxis or treatment of febrile neutropenia with 
biosimilars is cost-efficient.41 In the absence of convinc-
ing evidence that pegfilgrastim is pharmacotherapeutically 
superior to standard filgrastim, there is no cost-efficiency 
rationale to treat with that drug.40
The clinical and safety outcomes are well within the range 
of historically reported data for originator filgrastim, under-
scoring the clinical effectiveness and safety of biosimilar 
filgrastim in daily clinical practice.34–43
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